Hexyl methacrylate (HM) is a colorless liquid monomer that is used in the production of polymers, such as poly(hexyl methacrylate) (PHM). It is synthesized by the reaction of methacrylic acid with hexanol in the presence of an acid catalyst. HM is a versatile monomer that can be used to create polymers with a variety of properties, including high refractive index, low shrinkage, and good adhesion. It is used in a variety of applications, including optical lenses, adhesives, coatings, and dental materials. HM is also being studied for its potential use in biomedical applications, such as drug delivery and tissue engineering. '
hexyl methacrylate: used to make monolithic columns [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 8872 |
| CHEMBL ID | 1422108 |
| SCHEMBL ID | 33994 |
| MeSH ID | M0527815 |
| Synonym |
|---|
| nsc24169 |
| methacrylic acid, hexyl ester |
| nsc-24169 |
| hexyl methacrylate |
| ent 25419 |
| 142-09-6 |
| hexyl 2-methyl-2-propenoate |
| 2-propenoic acid, 2-methyl-, hexyl ester |
| NCGC00091065-01 |
| n-hexyl methacrylate |
| nsc 24169 |
| ai3-25419 |
| hsdb 5418 |
| einecs 205-521-9 |
| ccris 4824 |
| hexyl methacrylate, 98%, contains 100 ppm mehq |
| hexyl 2-methylacrylate |
| hexyl 2-methylprop-2-enoate |
| methacrylic acid hexyl ester |
| M0503 |
| NCGC00091065-02 |
| unii-538b2q3hsv |
| 538b2q3hsv , |
| dtxcid705406 |
| cas-142-09-6 |
| NCGC00257213-01 |
| dtxsid4025406 , |
| tox21_303323 |
| tox21_201680 |
| NCGC00259229-01 |
| FT-0627055 |
| AKOS015904101 |
| n-hexyl methacrylate [hsdb] |
| SCHEMBL33994 |
| hexyl 2-methylacrylate # |
| methacrylic acid n-hexyl ester |
| CHEMBL1422108 |
| mfcd00015283 |
| hexylmethacrylate |
| hexyl methacrylate, 98% |
| hexyl methacrylate (stabilized with mehq) |
| hexyl methacrylate, (stabilized with mehq) |
| J-007596 |
| n-hexylmethacrylate |
| Q27261083 |
| D97858 |
| CS-W017691 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 61.1306 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 7.9433 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 61.1306 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 10.8707 | 0.0010 | 22.6508 | 76.6163 | AID1224893 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 56.1935 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 38.9000 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 54.9477 | 0.0237 | 23.2282 | 63.5986 | AID743222 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 0.2753 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 29.8493 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 19.3312 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.08) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||